Category Archives: Uncategorized

26 Mar

Surface Oncology Plans IPO to Advance Clinical Tests of Cancer Drug

Cancer continues to be a big area of investor interest and Surface Oncology now aims to tap into that with

26 Mar

March 28 Webinar: Emerging Trends in Academic & Industry Collaboration

Novel collaborations between industry and academia are driving the commercialization of the next generation of biomedical cures. BIO One-on-One PartneringTM,

23 Mar

Auris Health’s Surgical Robot Gets FDA Green Light for Lung Cancer

Auris Health is now the latest surgical robot company with the go-ahead to enter the U.S. market. The Redwood City,

23 Mar

Flashback Friday: BIO ’97 Rodeo & Ranch Party

This post is part of BIO’s yearlong, bi-weekly series called Flashback Friday, highlighting newsletter stories from BIO’s past.  To learn

22 Mar

Research Headlines – Novel computational models to predict and prevent the next financial crisis

[Source: Research & Innovation] EU-funded researchers have developed novel mathematical models and tools to better prepare financial markets for the

22 Mar

Salim Yazji Joins PMV Pharma as Chief Medical Officer

PMV Pharmaceuticals has appointed Salim Yazji to serve as chief medical officer of the Cranbury, NJ, cancer drug developer. Yazji

22 Mar

San Antonio Bioscience and Technology Development Group Replaces CEO

San Antonio – The first CEO of VelocityTX, an emerging technology and startup resource center in San Antonio, has left the

21 Mar

Research Headlines – Promoting inclusion by rethinking Europe’s heritage

[Source: Research & Innovation] At a time when consensus on Europe’s past is breaking down, EU-funded researchers are rethinking the

21 Mar

At Opioid Hearing, BIO Exec Proposes Ways to Boost Pain Drug Development

After months of meetings and Congressional hearings on the unrelenting opioid addiction crisis, Congress has finally responded, with 25 bills

21 Mar

Highlighting History: Hong Kong’s New Listing Regime

Recent announcements that the Hong Kong Stock Exchange (HKEX) plans to allow the listing of pre-revenue biotech companies onto it’s